News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Accelovance Expands Oncology Leadership With the Addition of Ralph Boccia, MD as Oncology Medical Director



3/1/2013 10:16:26 AM

ROCKVILLE, Md., March 1, 2013 /PRNewswire-USNewswire/ -- Accelovance announces the addition of Ralph Boccia, MD, FACP as the Oncology Medical Director. The addition of Dr. Boccia is a strong compliment to the oncology strength the Maryland-based CRO that caters to biotech and small/mid pharma Sponsors. In addition to his responsibilities at Accelovance, Dr. Boccia is a founder and the Medical Director of the Center for Cancer and Blood Disorders. He also is an active Clinical Associate Professor of Medicine at Georgetown University and consulting Medical Director of the International Oncology Network (ION) Clinical Research Program.

Accelovance offers innovative clinical solutions focused on oncology that accelerate study start up timelines; existing partnerships with leading oncology academic institutions and improved access to target patient populations that in turn control study budgets. Such solutions are ideal for Phase I/II and ClinPharm studies where speed, quality and cost-effectiveness are critical to support Sponsor business goals. This model mirrors the highly successful approach utilized by Accelovance with their vaccine and infectious disease programs.

"We are thrilled to have a recognized leader in medical oncology and hematology, Dr. Ralph V. Boccia, join our organization. His 31 years of practice and clinical research are an asset to the clients we serve as we help define patient populations, study protocols and program approaches," remarked Stephen J. Trevisan, Accelovance President and Chief Executive Officer. "His addition complements our oncology experienced CRO team that has had tremendous growth over the last 12 months in clinical operations, project management and data management."

"It is a unique opportunity to join a forward-thinking, patient-centric clinical services company like Accelovance. This team's commitment to advancing the novel oncology therapies has real value to Sponsors. We are actively talking to companies with promising technology and it is quite exciting," commented Ralph V. Boccia, MD, FACP. He is a board-certified Medical Oncologist with specialties in internal medicine and hematology. Dr. Boccia earned his medical degree at the University of Minnesota and completed training in internal medicine at UCLA-affiliated hospitals. His hematology, oncology and bone marrow transplant fellowships were completed at the combined UCLA-VA program at the National Cancer Institute (NCI) at the National Institutes of Health in Bethesda, Maryland.

Headquartered in Rockville, Maryland, Accelovance is a privately held company that has developed a unique operational approach for delivering quality, on time, and cost effective clinical studies. The company was recognized as "Best CRO" with consecutive Industry Excellence awards in 2009, 2010 and 2011. The Company tailors its offering of full CRO, Clinical Sites, Patient Recruitment, and Call Center to present a clinical solution that meets a Sponsor's needs. Accelovance has a 100% owned subsidiary providing CRO services in China. These capabilities can assist clients with global development programs or product registration in China, the fastest growing pharmaceutical market in the world. Additionally, Accelovance offers six (6) wholly-owned, research-dedicated clinical sites to Sponsors and CROs that bring greater control, predictability, and quality assurance to therapeutically aligned studies.

For more information, visit the company's website at http://www.accelovance.com.

Media Contact:
Garrett D. Smith
Phone: 240.238.4914
gsmith@accelovance.com

SOURCE Accelovance


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES